Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
about
Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A reviewClinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsPrognostic value of circulating endothelial cells in metastatic colorectal cancer.NanoVelcro Chip for CTC enumeration in prostate cancer patients.Angiogenesis - still a worthwhile target for breast cancer therapy?CTC enumeration and characterization: moving toward personalized medicine.Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patientsPrognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer.Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentInterrelationships of circulating tumor cells with metastasis and thrombosis: role of microRNAsChemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB tClinical relevance and biology of circulating tumor cells.Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.Considerations in the development of circulating tumor cell technology for clinical useDynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis.Progress in using circulating tumor cell information to improve metastatic breast cancer therapyEstablishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancerCirculating tumor cells: advances in detection methods, biological issues, and clinical relevance.Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.Circulating tumor cells as emerging tumor biomarkers in breast cancer.Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer.Controversies in circulating tumor cell count during therapy.Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers.Crucial considerations for pipelines to validate circulating biomarkers for breast cancer.Circulating endothelial cells and their subsets: novel biomarkers for cancer.
P2860
Q26752116-4A86D7D5-F97C-47CC-9DCA-98E67CB85B1BQ26827936-520A0CDE-2E03-4450-BD4A-D1C21B709E95Q33913995-38DFF36C-9BC8-44F8-8F9B-69CB0BB7605DQ34354738-740B6098-DD81-4E16-AEC5-FB6F4A8884A0Q34423550-6D37D7B1-1375-49B5-9B3D-E31C3D1664AFQ34577724-CB823054-4A71-45C7-9AC2-7F54F9C7B1DEQ34996947-9427F709-8A7C-461A-9FE2-E01B2F56D9D8Q34999120-C227E8B5-69FA-4A09-A374-176E15E01F34Q35001280-26CAEAB9-309F-4760-98E0-CC3BFB35D8D3Q35028760-376E0EC6-CC91-4AA9-B130-01F53F71068AQ35427994-022B8AB2-F6C3-4DAB-B65D-784B160440E2Q35444368-82F4DFA7-186D-49D5-9F9B-0176F32786A9Q35519793-AC3F91BD-00A3-492A-A668-1C3A624925A7Q35558126-CDDE3732-D167-4BEF-A51F-52D9098DAF7FQ35664886-E02F35F0-85EC-4A3E-9F75-75AB7CCA08B1Q35815486-1478EF48-2C43-4334-9E60-4EFF979297FCQ35818839-2AB57DEB-55A6-4F15-BEB5-CF290CA130D8Q35863148-D4EB32E1-4A41-4971-9F6F-9E062E41F947Q35889548-07192974-2A68-4708-AF9D-6393A2521EDDQ36072794-29211C0B-1DA1-4666-8DB1-C4D24FF4EB18Q36182824-2D71226F-91B9-43C1-99D6-9203C190FA27Q36321612-E360C53F-23C3-4BE5-B7CF-B292A6D45384Q36338628-CA4065C4-5A12-48D0-B151-0E27DC22F4C1Q36387861-5E965BF6-6C80-45EE-8587-4D00CED5A9F7Q36406697-6909F87E-F830-4E4D-A357-B54855161F8CQ36551186-32C2A79D-6358-463A-B380-6D628129568CQ36752761-4431CD2E-E3BE-4778-86B6-08C17ABAE988Q36869787-C3D11E81-DFB5-4499-825F-D9CAED83063EQ37507435-1E11F5F1-C010-4E31-B825-3A172385A618Q37719099-3F7115F4-10EF-461C-9F9E-B9ACC5B769E6Q37890969-DD90C001-ECCA-4E09-A6A7-88993F682B2CQ37898107-333CE90B-854C-4B29-9645-4E9261F2EAD6Q37908134-CDD15CB4-280F-42DA-8565-0424F6982E13Q37950522-CD1CDB33-B4E2-49F2-8A09-418DC15F0826Q38046575-7FF30F8C-4539-43E4-8F5F-CA4E674BEB6EQ38070396-771D1E4E-11B3-4EAA-B6E9-520E65E7C2EBQ38115624-064575D8-0BFB-4000-9E4E-68A67ADEFB80Q38165245-DE48E12E-AA71-49CB-B96A-3C2323EAE2C1Q38665032-3B861BA6-D65F-4733-A57E-B93FDBBDB27BQ38672972-850DDC16-D410-436B-B866-49501760329D
P2860
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Clinical value of circulating ...... bevacizumab and chemotherapy.
@en
Clinical value of circulating ...... bevacizumab and chemotherapy.
@nl
type
label
Clinical value of circulating ...... bevacizumab and chemotherapy.
@en
Clinical value of circulating ...... bevacizumab and chemotherapy.
@nl
prefLabel
Clinical value of circulating ...... bevacizumab and chemotherapy.
@en
Clinical value of circulating ...... bevacizumab and chemotherapy.
@nl
P2093
P2860
P921
P356
P1433
P1476
Clinical value of circulating ...... h bevacizumab and chemotherapy
@en
P2093
A Degeorges
J-Y Pierga
L Bergougnoux
M-C Etienne-Grimaldi
P de Cremoux
P2860
P304
P356
10.1093/ANNONC/MDQ052
P577
2010-03-16T00:00:00Z